Pharmacokinetics of Oral and Intravenous Oseltamivir Treatment of Severe Influenza B Virus Infection Requiring Organ Replacement Therapy. (Q40748977)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26994602%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

title

Pharmacokinetics of Oral and Intravenous Oseltamivir Treatment of Severe Influenza B Virus Infection Requiring Organ Replacement Therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26994602%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

1 reference

Influenza B Virus

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26994602%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Roland C Francis

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26994602%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Felix Berger

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26994602%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Barbara Rath

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26994602%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

14

Brunhilde Schweiger

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26994602%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

13

Albert Osterhaus

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26994602%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

author name string

Katharina Karsch

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26994602%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Xi Chen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26994602%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Oliver Miera

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26994602%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Björn Peters

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26994602%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Válerie Amann

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26994602%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Susanne Duwe

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26994602%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Pieter Fraaij

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26994602%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Alla Heider

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26994602%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Marcel de Zwart

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26994602%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

language of work or name

1 reference

1 February 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26994602%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Drug Metabolism and Pharmacokinetics

11 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26994602%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

volume

42

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26994602%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26994602%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

page(s)

155-164

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26994602%20AND%20SRC:MED&resulttype=core&format=json

Influenza myocarditis and myositis: case presentation and review of the literature

11 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0330-9

Epidemiological features of influenza in Canadian adult intensive care unit patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0330-9

Influenza-associated hospitalizations in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0330-9

Intensive care adult patients with severe respiratory failure caused by Influenza A (H1N1)v in Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0330-9

High Satisfaction Rating by Users of Private-for-profit Healthcare Providers-evidence from a Cross-sectional Survey Among Inpatients of a Private Tertiary Level Hospital of North India

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0330-9

Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0330-9

Editorial commentary. "Late" treatment with neuraminidase inhibitors for severely ill patients with influenza: better late than never?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0330-9

Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0330-9

Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0330-9

Peramivir and laninamivir susceptibility of circulating influenza A and B viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0330-9

Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0330-9

Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0330-9

Population pharmacokinetic analysis of oseltamivir and oseltamivir carboxylate following intravenous and oral administration to patients with and without renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0330-9

Pharmacokinetic assessment of peramivir in a hospitalized adult undergoing continuous venovenous hemofiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0330-9

Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0330-9

Drug clearance by continuous haemodiafiltration. Analysis of sieving coefficients and mass transfer coefficients of diffusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0330-9

Plasma concentrations of oseltamivir and oseltamivir carboxylate in critically ill children on extracorporeal membrane oxygenation support

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0330-9

Oseltamivir Dosing in Critically Ill Patients With Severe Influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0330-9

Impact of extracorporeal membrane oxygenation and continuous venovenous hemodiafiltration on the pharmacokinetics of oseltamivir carboxylate in critically ill patients with pandemic (H1N1) influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0330-9

Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0330-9

Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0330-9

Implications of antiviral resistance of influenza viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0330-9

An inception cohort study assessing the role of pneumococcal and other bacterial pathogens in children with influenza and ILI and a clinical decision model for stringent antibiotic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0330-9

Virus load kinetics and resistance development during oseltamivir treatment in infants and children infected with Influenza A(H1N1) 2009 and Influenza B viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0330-9

Differentiation of influenza B virus lineages Yamagata and Victoria by real-time PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0330-9

Genotypic and phenotypic resistance of pandemic A/H1N1 influenza viruses circulating in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0330-9

The posology of oseltamivir in infants with influenza infection using a population pharmacokinetic approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0330-9

Pharmacokinetics and safety of oseltamivir in patients with end-stage renal disease treated with automated peritoneal dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0330-9

Pharmacokinetics of high-dose oseltamivir in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0330-9

Oseltamivir carboxylate accumulation in a patient treated by haemodiafiltration and extracorporeal membrane oxygenation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0330-9

Clinical experience with intravenous zanamivir under an Emergency IND program in the United States (2011-2014).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0330-9

Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0330-9

Safety and pharmacokinetics of oseltamivir at standard and high dosages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0330-9

Pharmacokinetics and safety of intravenous oseltamivir in infants and children in open-label studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0330-9

A prospective observational study of oseltamivir safety and tolerability in infants and young children ≤24 months.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0330-9

Review of the clinical effectiveness of the neuraminidase inhibitors against influenza B viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0330-9

Quantitative influenza follow-up testing (QIFT)--a novel biomarker for the monitoring of disease activity at the point-of-care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0330-9

Viral shedding in children infected by pandemic A/H1N1/2009 influenza virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0330-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0330-9

Influenza-associated intensive-care unit admissions and deaths - California, September 29, 2013-January 18, 2014.

21 January 2018

1 reference

12 December 2020

Influenza viruses with reduced sensitivity to the neuraminidase inhibitor drugs in untreated young children

1 reference

12 December 2020

Oseltamivir pharmacokinetics in critically ill adults receiving extracorporeal membrane oxygenation support.

1 reference

12 December 2020

Pharmacokinetics of oseltamivir carboxylate in critically ill patients: each patient is unique

1 reference

12 December 2020

Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP).

1 reference

12 December 2020

An in vitro study of the elimination of oseltamivir carboxylate by haemofiltration

1 reference

12 December 2020

Peramivir: an intravenous neuraminidase inhibitor

1 reference

12 December 2020

The pharmacokinetics of oseltamivir and oseltamivir carboxylate in a critically ill pediatric patient receiving extracorporeal membrane oxygenation and continuous venovenous hemodialysis

1 reference

12 December 2020

Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations

1 reference

12 December 2020

H1N1-infected Patients in ICU and Their Clinical Outcome

1 reference

12 December 2020